CDC 研究认为 Moderna 疫苗最有效,辉瑞和强生疫苗也能起到很好的保护作用

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
24,229
荣誉分数
5,924
声望点数
373

最新研究,Moderna似乎效果更好......​


来源: stillthere 于 2021-07-10 19:24:55
image.png

新冠突变病毒株的不断出现和在世界上多个国家和地区的广泛流行,让新冠疫苗能否对这些病毒株产生保护作用成为人们持续关注的问题。今天,《自然-医学》(Nature Medicine)上发表了一项来自卡塔尔(Qatar)的真实世界研究,评估了Moderna公司开发的mRNA-1273疫苗针对突变病毒株Alpha(B.1.1.7)和Beta(B.1.351)的防护效力。



研究结果显示,接种两剂mRNA-1273两周后,防护Alpha感染的效力为100%,防护Beta感染的效力为96.4%,防护由于任何新冠病毒株造成的严重、危重、或死亡COVID-19病例的效力为95.7%。

卡塔尔在今年2月下旬开始大规模疫苗接种,在疫苗接种活动扩展的过程中,由于Alpha和Beta突变株的引入和扩展,该国出现了两次COVID-19的爆发。论文指出,这提供了一个利用真实世界数据,评估疫苗针对受到关注的突变株的真实世界效力的机会。

研究人员使用了称为检测阴性病例对照(test-negative case-control)的研究方法,对超过5万人的接种情况和感染情况进行了分析。这种研究方法是研究疫苗有效性时的一种常用方法,它的好处在于可以降低疫苗接种组和未接种组之间在求医行为上的差异(例如,接种过新冠疫苗的人如果出现感冒症状可能不会马上去做核酸检测,而未接种过新冠疫苗的人可能会更积极地去做核酸检测)。

image.png


分析结果显示,针对Alpha突变株,预防病毒感染的效果在接种第一剂疫苗后两周内很有限,不过随后迅速增长,在接种后第四周(接种第二剂疫苗前)达到94.4%(95% CI: 95.3–100.0%)。在接种第二剂疫苗14天后,防护效力为100%(95% CI: 91.8–100.0%)。

image.png

▲mRNA-1273对Alpha突变株感染的防护能力随接种次数和时间的变化

针对Beta突变株,预防病毒感染的效果走向与Alpha类似,在接种第一剂疫苗后头两周保护效力有限,在接种后第四周(接种第二剂疫苗前)达到73.7%(95% CI: 67.6–78.8%)。在接种第二剂疫苗14天后,防护效力为96.4%(95% CI: 91.9–98.7%)。

image.png

▲mRNA-1273对Beta突变株感染的防护能力随接种次数和时间的变化

针对因为任何新冠病毒感染造成的严重、危重和致命疾病,疫苗的有效性在接种一剂疫苗后第四周(接种第二剂疫苗前)达到92.1%(95% CI: 78.4–97.9%)。在接种第二剂疫苗14天后,防护效力为95.7%(95% CI: 91.9–98.7%)。

image.png

▲mRNA-1273对严重、危重和致命COVID-19疾病的防护效力随接种次数和时间的变化(图片来源:参考资料[1])

研究人员还使用了名为队列研究设计(cohort study design)的方法对mRNA-1273的防护效力进行了评估。结果显示,mRNA-1273防护Alpha感染的效力为100.0%(95% CI: 82.5–100.0%),防护Beta感染的效力为87.8%(95% CI: 73.4–95.5%),与使用检测阴性病例对照方法得出的疫苗保护效力相似。

研究人员在论文的讨论环节指出,分析结果显示,无论是针对Alpha还是Beta突变株,mRNA-1273都表现出高度防护效果,并且可以预防因为COVID-19导致的住院和死亡。对病毒的防护效力在接种第一剂疫苗第三周之后显著提高,针对Beta病毒株,防护效力的上升相对较慢,接种第二剂疫苗能够提供最大程度的保护。

 
最后编辑:
注册
2014-02-10
消息
1,689
荣誉分数
259
声望点数
93
所在地
Ottawa
研究结果显示,接种两剂mRNA-1273两周后,防护Alpha感染的效力为100%,防护Beta感染的效力为96.4%,防护由于任何新冠病毒株造成的严重、危重、或死亡COVID-19病例的效力为95.7%
没有死亡,为什么还用95.7%不用防止死亡100%
 

Jay Wang

薄皮大馅
VIP
注册
2008-05-09
消息
25,738
荣誉分数
5,269
声望点数
373
发骚打摆子,值了!
 

joe_xj

资深人士
VIP
注册
2007-06-11
消息
2,913
荣誉分数
493
声望点数
243
我都记不住,当初说Moderna不好的点有哪些? 是副作用比较大吗? 现在怎么看待原来不看好的那些点的?
 

klee19444

知名会员
注册
2004-04-07
消息
81
荣誉分数
2
声望点数
118
每剂Moderna 含100微克 mRNA, 每剂Pfizer 含30微克 mRNA.
 

billwanhua

本站元老
注册
2005-07-07
消息
4,748
荣誉分数
1,358
声望点数
373
836025bagy1gshrbgknozj20xc0wvgsb.jpg


斯坦福小规模实验发现辉瑞更好,而且看起来数字好很多,辉瑞 73%下降三倍以内,跟以色列实际防护率差不多,下降超过三倍就危险了
 
最后编辑:

billwanhua

本站元老
注册
2005-07-07
消息
4,748
荣誉分数
1,358
声望点数
373
每剂Moderna 含100微克 mRNA, 每剂Pfizer 含30微克 mRNA.
不一样的厂家,剂量大的往往不能说明更好,效果不够才增加剂量
 

lindamy

时代广场舞照跳
VIP
注册
2005-11-23
消息
24,229
荣誉分数
5,924
声望点数
373
1 hr 20 min ago

CDC-led study finds Moderna Covid-19 vaccine most effective, but Pfizer and J&J shots also protect well

From CNN's Maggie Fox

Moderna vaccine vials are seen at a mass Covid-19 vaccination event on September 15 in Dusun Bambu, Indonesia.
Moderna vaccine vials are seen at a mass Covid-19 vaccination event on September 15 in Dusun Bambu, Indonesia. (Algi Febri Sugita/SOPA Images/LightRocket/Getty Images)

A head-to-head study of all three authorized coronavirus vaccines in the United States finds the Moderna vaccine is slightly more effective than Pfizer’s in real-life use in keeping people out of the hospital, and Johnson & Johnson’s Janssen vaccine comes in third, but still providing 71% protection.

Pfizer’s vaccine provided 88% protection against hospitalization, and Moderna’s was 93% effective.
The US Centers for Disease Control and Prevention led a nationwide study of vaccination involving more than 3,600 adults hospitalized for Covid-19 between March and August.


“Among U.S. adults without immunocompromising conditions, vaccine effectiveness against COVID-19 hospitalization during March 11–August 15, 2021, was higher for the Moderna vaccine (93%) than the Pfizer-BioNTech vaccine (88%) and the Janssen vaccine (71%),” the team wrote in the CDC’s weekly report on death and disease, the MMWR.

“Although these real-world data suggest some variation in levels of protection by vaccine, all FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.”

They found that the biggest difference between the vaccine made by Moderna and Pfizer/BioNtech’s vaccine was driven by a decline that started about four months after people were fully vaccinated with Pfizer’s vaccine.

“Differences in vaccine effectiveness between the Moderna and Pfizer-BioNTech vaccine might be due to higher mRNA content in the Moderna vaccine, differences in timing between doses (3 weeks for Pfizer-BioNTech versus 4 weeks for Moderna), or possible differences between groups that received each vaccine that were not accounted for in the analysis,” the team wrote.

“A single dose of the Janssen viral vector vaccine had comparatively lower anti-SARS-CoV-2 antibody response and vaccine effectiveness against COVID-19 hospitalizations,” they added. “Understanding differences in vaccine effectiveness by vaccine product can guide individual choices and policy recommendations regarding vaccine boosters. All FDA-approved or authorized COVID-19 vaccines provide substantial protection against COVID-19 hospitalization.”

CDC worked with researchers across the country to study 3,689 patients at 21 hospitals in 18 states for the study. They also looked at antibodies in the blood of 100 healthy volunteers after they’d been vaccinated with one of the three available vaccines.

The news comes as vaccine advisers to the US Food and Drug Administration meet Friday to discuss whether many Americans need to start getting booster doses of coronavirus vaccine.


BREAKING NEWS
 
顶部